Acquisition provides assets targeting the tumor stroma and myeloid cells
These new programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim’s position in cancer immunology, with leading assets and robust capabilities in cancer vaccines, oncolytic viruses, T-cell engagers and myeloid cell modulators
Acquisition of Versant-built company based in Toronto’s MaRS Discovery District
歡迎光臨 喜市股票討論區 (http://hei-market.com/) | Powered by Discuz! 6.1.0F |